135 related articles for article (PubMed ID: 11435263)
1. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study.
Allgulander C; Hackett D; Salinas E
Br J Psychiatry; 2001 Jul; 179():15-22. PubMed ID: 11435263
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.
Gelenberg AJ; Lydiard RB; Rudolph RL; Aguiar L; Haskins JT; Salinas E
JAMA; 2000 Jun; 283(23):3082-8. PubMed ID: 10865302
[TBL] [Abstract][Full Text] [Related]
3. Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trials.
Katz IR; Reynolds CF; Alexopoulos GS; Hackett D
J Am Geriatr Soc; 2002 Jan; 50(1):18-25. PubMed ID: 12028242
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial.
Stein MB; Pollack MH; Bystritsky A; Kelsey JE; Mangano RM
Psychopharmacology (Berl); 2005 Jan; 177(3):280-8. PubMed ID: 15258718
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of venlafaxine, extended release formulation, in the short-term and long-term treatment of generalized anxiety disorder: results of a survival analysis.
Montgomery SA; Mahé V; Haudiquet V; Hackett D
J Clin Psychopharmacol; 2002 Dec; 22(6):561-7. PubMed ID: 12454555
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder.
Rickels K; Pollack MH; Sheehan DV; Haskins JT
Am J Psychiatry; 2000 Jun; 157(6):968-74. PubMed ID: 10831478
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine.
Allgulander C; Mangano R; Zhang J; Dahl AA; Lepola U; Sjödin I; Emilien G;
Hum Psychopharmacol; 2004 Aug; 19(6):387-96. PubMed ID: 15303242
[TBL] [Abstract][Full Text] [Related]
8. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases.
Keller MB; Trivedi MH; Thase ME; Shelton RC; Kornstein SG; Nemeroff CB; Friedman ES; Gelenberg AJ; Kocsis JH; Dunner DL; Hirschfeld RM; Rothschild AJ; Ferguson JM; Schatzberg AF; Zajecka JM; Pedersen RD; Yan B; Ahmed S; Musgnung J; Ninan PT
J Clin Psychiatry; 2007 Aug; 68(8):1246-56. PubMed ID: 17854250
[TBL] [Abstract][Full Text] [Related]
9. Social adjustment in generalised anxiety disorder: a long-term placebo-controlled study of venlafaxine extended release.
Boyer P; Mahé V; Hackett D
Eur Psychiatry; 2004 Aug; 19(5):272-9. PubMed ID: 15276659
[TBL] [Abstract][Full Text] [Related]
10. Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study.
Davidson J; Rothbaum BO; Tucker P; Asnis G; Benattia I; Musgnung JJ
J Clin Psychopharmacol; 2006 Jun; 26(3):259-67. PubMed ID: 16702890
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of long-term venlafaxine XR therapy for GAD. Results of long-term, double-blind, placebo-controlled studies.
Lydiard RB
Postgrad Med; 1999 Nov; 106(6 Suppl):17-23. PubMed ID: 19667500
[TBL] [Abstract][Full Text] [Related]
12. Venlafaxine XR in the treatment of anxiety.
Hackett D
Acta Psychiatr Scand Suppl; 2000; (406):30-5. PubMed ID: 11131468
[TBL] [Abstract][Full Text] [Related]
13. Time to relapse after 6 and 12 months' treatment of generalized anxiety disorder with venlafaxine extended release.
Rickels K; Etemad B; Khalid-Khan S; Lohoff FW; Rynn MA; Gallop RJ
Arch Gen Psychiatry; 2010 Dec; 67(12):1274-81. PubMed ID: 21135327
[TBL] [Abstract][Full Text] [Related]
14. Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder.
Bose A; Korotzer A; Gommoll C; Li D
Depress Anxiety; 2008; 25(10):854-61. PubMed ID: 18050245
[TBL] [Abstract][Full Text] [Related]
15. A double-blind, randomised, placebo controlled study of venlafaxine XL in patients with generalised anxiety disorder in primary care.
Lenox-Smith AJ; Reynolds A
Br J Gen Pract; 2003 Oct; 53(495):772-7. PubMed ID: 14601352
[TBL] [Abstract][Full Text] [Related]
16. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder.
Pollack MH; Lepola U; Koponen H; Simon NM; Worthington JJ; Emilien G; Tzanis E; Salinas E; Whitaker T; Gao B
Depress Anxiety; 2007; 24(1):1-14. PubMed ID: 16894619
[TBL] [Abstract][Full Text] [Related]
17. Assessing the efficacy of 2 years of maintenance treatment with venlafaxine extended release 75-225 mg/day in patients with recurrent major depression: a secondary analysis of data from the PREVENT study.
Kornstein SG; Kocsis JH; Ahmed S; Thase M; Friedman ES; Dunlop BW; Yan B; Pedersen R; Ninan PT; Li T; Keller M
Int Clin Psychopharmacol; 2008 Nov; 23(6):357-63. PubMed ID: 18854724
[TBL] [Abstract][Full Text] [Related]
18. A meta-analysis of the efficacy of venlafaxine extended release 75-225 mg/day for the treatment of major depressive disorder.
Thase M; Asami Y; Wajsbrot D; Dorries K; Boucher M; Pappadopulos E
Curr Med Res Opin; 2017 Feb; 33(2):317-326. PubMed ID: 27794623
[TBL] [Abstract][Full Text] [Related]
19. Venlafaxine extended release (XR) in the treatment of generalized anxiety disorder.
Sheehan DV
J Clin Psychiatry; 1999; 60 Suppl 22():23-8. PubMed ID: 10634352
[TBL] [Abstract][Full Text] [Related]
20. Attaining remission in generalized anxiety disorder: venlafaxine extended release comparative data.
Sheehan DV
J Clin Psychiatry; 2001; 62 Suppl 19():26-31. PubMed ID: 11577788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
